Complex of human HDAC3, GenBank Accession No. NM_003883, a.a. 1-428(end) with C-terminal His-tag, MW= 50 kDa, and human NCOR2, GenBank Accession No. NM_006312, a.a 395-489 with N-terminal GST tag, MW= 38 kDa, co-expressed in baculovirus expression system.

histone deacetylase 3, HDAC-3

≥3000 pmol/min/µg.

25 mM Tris/HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl₂, and 0.1 mg/ml BSA, 20 µM BPS HDAC substrate 3 (Catalog #50037), and HDAC3/NcoR2. Incubation condition: 30 min at 37°C, followed by HDAC developer (Catalog #50030) for 15 min at room temperature. Fluorescence intensity is measured at ex360/em460.

40 mM Tris-HCl pH 8.0, 110 mM NaCl, 2.2 mM KCl, 250 mM Imidazole and 20% glycerol.

Aqueous buffer solution

At least 6 months at –80°C

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Gregoire, S. et al. Mol. Cell. Biol. 27 (4), 1280-1295 (2007)
2. Escaffit, F. et al., Mol. Cell. Biol. 27 (2), 554-567 (2007)

Application Reference(s):
1. Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia (2017)
2. An azumamide C analogue without the zinc-binding functionality (2017)
3. Molecular Simulation and Activity Studies of Oxametacin as an HDAC Inhibitor (2017)
4. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017)
5. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif (2017)
6. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases (2015)
7. Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich's Ataxia (2015)
8. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014)
9. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1 (2014)
10. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy (2014)
11. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014)
12. Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection (2014)
13. Class I HDAC imaging using [ (3)H]CI-994 autoradiography (2013)
14. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013)
15. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013)
16. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013)
17. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA (2013)
18. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni (2013)

Avoid freeze/thaw cycles.

Deacetylase

Recombinant Protein